Sandoz to Acquire CIMERLI from Coherus for $170 Million
Big Molecule Watch
FEBRUARY 6, 2024
On January 22, 2024, Sandoz announced its plans to acquire the U.S. biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. According to Sandoz, “closing is anticipated in 1H 2024, subject to standard conditions and approval.” Coherus”) for an upfront cash purchase payment of USD 170 million.
Let's personalize your content